LB PHARMACEUTICALS INITIATES PIVOTAL PHASE 3 TRIAL (NOVA-2) FOR LB-102 IN PATIENTS WITH SCHIZOPHRENIA
LB PHARMACEUTICALS INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2027
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.